Quantcast

Latest insulin pump Stories

2010-06-28 15:30:00

SAN DIEGO, June 28 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced clinical trial results showing that the addition of its proprietary rHuPH20 (recombinant human hyaluronidase, PH20) enzyme to three different mealtime insulin analogs accelerated their absorption. The acceleration produced by the coadministration of rHuPH20 produced significantly more pronounced insulin effects during the first hour after injection as well as a more rapid diminution of...

2010-06-24 05:23:00

DALLAS, Texas, June 24, 2010 /PRNewswire/ -- ReportsandReports announces it will carry the Diabetes Care Devices Market in Brazil, Russia, India, and China (BRIC) (2010 - 2014) Market Research Report in its store. Browse the complete Report on: http://www.reportsandreports.com/market-reports/diabetes-care-devices-mar ket-in-brazil-russia-india-and-china-/ (Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL...

2010-06-23 09:34:00

LAUSANNE, Switzerland and GENEVA, June 23 /PRNewswire-FirstCall/ -- Debiotech and STMicroelectronics (NYSE: STM) today announced that they will publicly showcase their novel insulin "Jewel Pump" at the Debiotech stand at the American Diabetes Association 70th Scientific Sessions (June 25-29) in Orlando, Florida. Representing the most advanced use of microfluidic MEMS (Micro-Electro-Mechanical Systems) technology in diabetes treatment, the tiny device, for which FDA clearance is now...

2010-06-16 04:00:00

LONDON, June 16 /PRNewswire/ -- The continuous glucose monitoring (CGM) market is in its development stage. The primary factor leading to the growth of the (CGM) market in Europe is the need for an easy-to-use and patient-friendly glucose-monitoring device. The traditional method of monitoring glucose was difficult and inconvenient for patients. The CGM method is not only hassle-free, but also gives a better diagnosis of diabetes. (Logo:...

2010-06-09 13:15:43

Highlighted in special issue of Diabetes Technology & Therapeutics The growing use of insulin delivery devices such as pens and pumps may help individuals with diabetes optimize blood glucose control and minimize their risk for chronic health problems associated with diabetes, as described in a Special Supplement to Diabetes Technology & Therapeutics, a peer-reviewed journal published by Mary Ann Liebert, Inc. (http://www.liebertpub.com). The issue is available free online...

2010-05-03 07:45:00

PRINCETON, N.J., May 3 /PRNewswire/ -- Novo Nordisk is launching an online photo contest to help change the way people think about taking insulin. The "Where Have You Flexed" contest is open to patients who use Levemir® FlexPen® (insulin detemir [rDNA origin] injection), NovoLog® FlexPen® (insulin aspart [rDNA origin] injection), and NovoLog® Mix 70/30 FlexPen® (70% insulin aspart...

2010-04-20 06:00:00

BEDFORD, Mass., April 20 /PRNewswire-FirstCall/ -- Insulet Corporation (Nasdaq: PODD), the leader in tubing-free insulin pump technology with its OmniPod® Insulin Management System announced plans to release its financial results for the first quarter of 2010 on Thursday, May 6, 2010 after the close of the financial markets. Insulet will also host a conference call at 5:00 p.m. Eastern Time on Thursday, May 6, 2010 to discuss its first quarter 2010 financial results....

2010-04-13 07:00:00

MONTREUX, Switzerland, April 13 /PRNewswire/ -- CeQur SA, a company focused on the development and commercialization of insulin delivery systems to improve the management of type 2 diabetes, announced the appointment of Robert O'Holla as executive vice president for regulatory affairs, effective May 1. O'Holla previously spent 33 years at Johnson and Johnson, where, for the last 18 years, he served as worldwide vice president for regulatory affairs. While at J&J, he oversaw numerous...

2010-02-05 14:15:37

Scientists in Cambridge have made a significant step towards developing a so-called "artificial pancreas" system for managing type 1 diabetes in children. The team has developed and successfully tested a new algorithm, providing a stepping stone to home testing for the artificial pancreas. The new study "“ funded by Juvenile Diabetes Research Foundation (JDRF) and published today in The Lancet "“ shows that using an artificial pancreas system overnight can significantly reduce the...

2010-01-19 13:00:00

R&D Program Targets Opportunities to Improve Glucose Control and Help People with Diabetes Lead Healthier Lives NEW YORK and FRANKLIN LAKES, N.J., Jan. 19 /PRNewswire-USNewswire/ -- The Juvenile Diabetes Research Foundation (JDRF) and BD (Becton, Dickinson and Company) (NYSE: BDX) announced today an innovative program aimed at improving the treatment of type 1 diabetes by developing novel insulin delivery products to enhance the use of insulin pumps. Through the program, JDRF will...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related